Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17.
J Clin Oncol. 2021.
PMID: 34138638
Clinical Trial.
Spleen response ( 35% spleen volume reduction) and symptom response ( 50% reduction in total symptom score) rates at week 24 were coprimary end points. Secondary end points included OS and safety. ...
Spleen response ( 35% spleen volume reduction) and symptom response ( 50% reduction in total symptom score) rates at week 24 were cop …
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R.
Kuykendall AT, et al.
Ann Hematol. 2022 Jan;101(1):139-146. doi: 10.1007/s00277-021-04683-w. Epub 2021 Oct 8.
Ann Hematol. 2022.
PMID: 34622316
Clinical Trial.
Overall survival was measured from time of JAK inhibitor discontinuation to death or censored at last follow-up. To improve comparability, propensity score weighting approaches using average treatment effect for overlap population (ATO) and stabilized inverse probability t …
Overall survival was measured from time of JAK inhibitor discontinuation to death or censored at last follow-up. To improve comparability, p …
Item in Clipboard
Cite
Cite